Compare e l f Beauty Inc (ELF) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Novartis AG — how do they compare? e l f Beauty Inc trades at $74.47 (market cap $4.37B), while Novartis AG trades at $150.91 (market cap $287.66B). The key difference: Novartis AG is far larger — about 65.8× e l f Beauty Inc's market cap, and Novartis AG pays a 3.14% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.
| ELF | NVS | |
|---|---|---|
Market Cap | $4.37B | $287.66B |
Sector | Technology | Health |
52-Week High | $146.67 | $168.62 |
52-Week Low | $49.57 | $113.50 |
Enterprise Value | $5.00B | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $74.77, up 3.49% with a bullish technical signal supported by moving averages. The company shows strong revenue growth reaching $1.31B in 2025 but faces margin compression with net income margin at 1.61%. Recent earnings beats and analyst coverage skewed toward buy/hold suggest cautious optimism. Technical indicators show support at $73 and resistance at $76, with RSI neutral but ADX signaling strong trend momentum.
Outlook remains mixed: growth initiatives in skincare and international markets provide upside, but high P/E of 168.68 and margin pressures pose valuation risks. Analyst consensus target of $74.42 aligns with current price, indicating limited near-term upside. Key risks include competitive pressures and execution on brand expansion.
NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).
The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
